119 related articles for article (PubMed ID: 27129164)
1. SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth.
Park SY; Na Y; Lee MH; Seo JS; Lee YH; Choi KC; Choi HK; Yoon HG
Oncotarget; 2016 Jul; 7(27):41110-41122. PubMed ID: 27129164
[TBL] [Abstract][Full Text] [Related]
2. Reversible SUMOylation of TBL1-TBLR1 regulates β-catenin-mediated Wnt signaling.
Choi HK; Choi KC; Yoo JY; Song M; Ko SJ; Kim CH; Ahn JH; Chun KH; Yook JI; Yoon HG
Mol Cell; 2011 Jul; 43(2):203-16. PubMed ID: 21777810
[TBL] [Abstract][Full Text] [Related]
3. SENP2 regulates MMP13 expression in a bladder cancer cell line through SUMOylation of TBL1/TBLR1.
Tan M; Gong H; Wang J; Tao L; Xu D; Bao E; Liu Z; Qiu J
Sci Rep; 2015 Sep; 5():13996. PubMed ID: 26369384
[TBL] [Abstract][Full Text] [Related]
4. Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation.
Daniels G; Zhang X; Zhong X; Santiago L; Wang LH; Wu X; Zhang JY; Liang F; Li X; Neubert TA; Steinke L; Shen Y; Basch R; Schneider R; Levy DE; Lee P
Oncotarget; 2016 Jun; 7(26):39556-39571. PubMed ID: 27127173
[TBL] [Abstract][Full Text] [Related]
5. TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis.
Li J; Wang CY
Nat Cell Biol; 2008 Feb; 10(2):160-9. PubMed ID: 18193033
[TBL] [Abstract][Full Text] [Related]
6. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.
Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P
Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687
[TBL] [Abstract][Full Text] [Related]
7. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1.
Yoon HG; Chan DW; Huang ZQ; Li J; Fondell JD; Qin J; Wong J
EMBO J; 2003 Mar; 22(6):1336-46. PubMed ID: 12628926
[TBL] [Abstract][Full Text] [Related]
8. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints.
Perissi V; Scafoglio C; Zhang J; Ohgi KA; Rose DW; Glass CK; Rosenfeld MG
Mol Cell; 2008 Mar; 29(6):755-66. PubMed ID: 18374649
[TBL] [Abstract][Full Text] [Related]
9. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors.
Perissi V; Aggarwal A; Glass CK; Rose DW; Rosenfeld MG
Cell; 2004 Feb; 116(4):511-26. PubMed ID: 14980219
[TBL] [Abstract][Full Text] [Related]
10. Structure of the MeCP2-TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders.
Kruusvee V; Lyst MJ; Taylor C; Tarnauskaitė Ž; Bird AP; Cook AG
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):E3243-E3250. PubMed ID: 28348241
[TBL] [Abstract][Full Text] [Related]
11. TBLR1 regulates the expression of nuclear hormone receptor co-repressors.
Zhang XM; Chang Q; Zeng L; Gu J; Brown S; Basch RS
BMC Cell Biol; 2006 Aug; 7():31. PubMed ID: 16893456
[TBL] [Abstract][Full Text] [Related]
12. Transducin (Beta)-Like 1 X-Linked Receptor 1 Correlates with Clinical Prognosis and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.
Kuang X; Zhu J; Peng Z; Wang J; Chen Z
Dig Dis Sci; 2016 Feb; 61(2):489-500. PubMed ID: 26386862
[TBL] [Abstract][Full Text] [Related]
13. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia.
Kulozik P; Jones A; Mattijssen F; Rose AJ; Reimann A; Strzoda D; Kleinsorg S; Raupp C; Kleinschmidt J; Müller-Decker K; Wahli W; Sticht C; Gretz N; von Loeffelholz C; Stockmann M; Pfeiffer A; Stöhr S; Dallinga-Thie GM; Nawroth PP; Diaz MB; Herzig S
Cell Metab; 2011 Apr; 13(4):389-400. PubMed ID: 21459324
[TBL] [Abstract][Full Text] [Related]
14. Transducin (β)-like 1 X-linked receptor 1 promotes proliferation and tumorigenicity in human breast cancer via activation of beta-catenin signaling.
Li X; Liang W; Liu J; Lin C; Wu S; Song L; Yuan Z
Breast Cancer Res; 2014 Oct; 16(5):465. PubMed ID: 25341494
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
[TBL] [Abstract][Full Text] [Related]
16. Transducin β-like protein 1 recruits nuclear factor κB to the target gene promoter for transcriptional activation.
Ramadoss S; Li J; Ding X; Al Hezaimi K; Wang CY
Mol Cell Biol; 2011 Mar; 31(5):924-34. PubMed ID: 21189284
[TBL] [Abstract][Full Text] [Related]
17. Reading and function of a histone code involved in targeting corepressor complexes for repression.
Yoon HG; Choi Y; Cole PA; Wong J
Mol Cell Biol; 2005 Jan; 25(1):324-35. PubMed ID: 15601853
[TBL] [Abstract][Full Text] [Related]
18. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.
Zheng Z; Cai C; Omwancha J; Chen SY; Baslan T; Shemshedini L
J Biol Chem; 2006 Feb; 281(7):4002-12. PubMed ID: 16361251
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
20. Nimbolide inhibits androgen independent prostate cancer cells survival and proliferation by modulating multiple pro-survival signaling pathways.
Singh PR; Priya ES; Balakrishnan S; Arunkumar R; Sharmila G; Rajalakshmi M; Arunakaran J
Biomed Pharmacother; 2016 Dec; 84():1623-1634. PubMed ID: 27889231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
